797 related articles for article (PubMed ID: 24314876)
21. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
23. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.
Giamarellos-Bourboulis EJ; Pelekanou E; Antonopoulou A; Petropoulou H; Baziaka F; Karagianni V; Stavrianeas N; Giamarellou H
Br J Dermatol; 2008 Mar; 158(3):567-72. PubMed ID: 18076705
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
[TBL] [Abstract][Full Text] [Related]
26. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
27. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions.
van der Zee HH; Prens EP; Boer J
J Am Acad Dermatol; 2010 Sep; 63(3):475-80. PubMed ID: 20708472
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa.
Lesage C; Adnot-Desanlis L; Perceau G; Bonnet M; Palot JP; Bernard P; Reguiaï Z
Eur J Dermatol; 2012; 22(5):640-4. PubMed ID: 22759562
[TBL] [Abstract][Full Text] [Related]
29. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
30. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
Ghias MH; Johnston AD; Kutner AJ; Micheletti RG; Hosgood HD; Cohen SR
J Am Acad Dermatol; 2020 May; 82(5):1094-1101. PubMed ID: 31589948
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.
Join-Lambert O; Coignard-Biehler H; Jais JP; Delage M; Guet-Revillet H; Poirée S; Duchatelet S; Jullien V; Hovnanian A; Lortholary O; Nassif X; Nassif A
J Antimicrob Chemother; 2016 Feb; 71(2):513-20. PubMed ID: 26565016
[TBL] [Abstract][Full Text] [Related]
32. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.
van der Zee HH; Boer J; Prens EP; Jemec GB
Dermatology; 2009; 219(2):143-7. PubMed ID: 19590174
[TBL] [Abstract][Full Text] [Related]
33. Metformin for the treatment of hidradenitis suppurativa: a little help along the way.
Verdolini R; Clayton N; Smith A; Alwash N; Mannello B
J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1101-8. PubMed ID: 22882365
[TBL] [Abstract][Full Text] [Related]
34. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
35. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients.
Matusiak L; Bieniek A; Szepietowski JC
Br J Dermatol; 2014 Jul; 171(1):170-4. PubMed ID: 24506875
[TBL] [Abstract][Full Text] [Related]
36. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa.
Yildiz H; Senol L; Ercan E; Bilgili ME; Karabudak Abuaf O
Int J Dermatol; 2016 Feb; 55(2):232-7. PubMed ID: 26267600
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa.
Romaní J; Vilarrasa E; Martorell A; Fuertes I; Ciudad C; Molina-Leyva A
Dermatology; 2020; 236(1):21-24. PubMed ID: 31288233
[TBL] [Abstract][Full Text] [Related]
38. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.
Sartorius K; Emtestam L; Jemec GB; Lapins J
Br J Dermatol; 2009 Oct; 161(4):831-9. PubMed ID: 19438453
[TBL] [Abstract][Full Text] [Related]
39. Surgical treatment of severe hidradenitis suppurativa of the axilla: thoracodorsal artery perforator (TDAP) flap versus split skin graft.
Wormald JC; Balzano A; Clibbon JJ; Figus A
J Plast Reconstr Aesthet Surg; 2014 Aug; 67(8):1118-24. PubMed ID: 24933237
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
